Bipolar Disorder — Dietary Intervention for Bipolar Disorder
Citation(s)
aan het Rot M, Hogenelst K, Schoevers RA Mood disorders in everyday life: a systematic review of experience sampling and ecological momentary assessment studies. Clin Psychol Rev. 2012 Aug;32(6):510-23. doi: 10.1016/j.cpr.2012.05.007. Epub 2012 Jun 6. Review.
Basselin M, Kim HW, Chen M, Ma K, Rapoport SI, Murphy RC, Farias SE Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation. J Lipid Res. 2010 May;51(5):1049-56. doi: 10.1194/jlr.M002469. Epub 2009 Dec 29. Retraction in: J Lipid Res. 2018 Aug;59(8):1547.
Bauer J, Gottfries GG, Förstl H Critical comments on "Propionibacterium acnes in the cortex of patients with Alzheimer's disease" by H.H. Kornhuber (Eur Arch Psychiatry Clin Neurosci, 1996, 246:108-109). Eur Arch Psychiatry Clin Neurosci. 1996;246(4):224-6.
Bauer M, Glenn T, Grof P, Schmid R, Pfennig A, Whybrow PC Subsyndromal mood symptoms: a useful concept for maintenance studies of bipolar disorder? Psychopathology. 2010;43(1):1-7. doi: 10.1159/000255957. Epub 2009 Nov 6. Review.
Frangou S, Lewis M, McCrone P Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry. 2006 Jan;188:46-50.
Frangou S, Lewis M, Wollard J, Simmons A Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J Psychopharmacol. 2007 Jun;21(4):435-9. Epub 2006 Aug 4.
Hamer RM, Simpson PM Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry. 2009 Jun;166(6):639-41. doi: 10.1176/appi.ajp.2009.09040458.
Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr. 2006 Jun;83(6 Suppl):1483S-1493S. doi: 10.1093/ajcn/83.6.1483S.
Hibbeln JR, Palmer JW, Davis JM Are disturbances in lipid-protein interactions by phospholipase-A2 a predisposing factor in affective illness? Biol Psychiatry. 1989 Apr 1;25(7):945-61. Review.
Horne JA, Ostberg O A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4(2):97-110.
Jen A, Saunders EF, Ornstein RM, Kamali M, McInnis MG Impulsivity, anxiety, and alcohol misuse in bipolar disorder comorbid with eating disorders. Int J Bipolar Disord. 2013 Aug 6;1:13. doi: 10.1186/2194-7511-1-13. eCollection 2013.
Johns MW A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5.
Kim HW, Cheon Y, Modi HR, Rapoport SI, Rao JS Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brain. Psychopharmacology (Berl). 2012 Aug;222(4):663-74. doi: 10.1007/s00213-012-2671-7. Epub 2012 Mar 14.
Kim HW, Rapoport SI, Rao JS Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol Psychiatry. 2011 Apr;16(4):419-28. doi: 10.1038/mp.2009.137. Epub 2009 Dec 29.
Kim HW, Rapoport SI, Rao JS Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis. 2010 Mar;37(3):596-603. doi: 10.1016/j.nbd.2009.11.010. Epub 2009 Nov 26.
Lee HJ, Ertley RN, Rapoport SI, Bazinet RP, Rao JS Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex. Neurochem Res. 2008 May;33(5):861-6. Epub 2007 Dec 14.
Lee HJ, Rao JS, Chang L, Rapoport SI, Kim HW Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder? Mol Psychiatry. 2010 Jun;15(6):602-14. doi: 10.1038/mp.2008.117. Epub 2008 Nov 4.
Linde M, Mulleners WM, Chronicle EP, McCrory DC Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013 Jun 24;(6):CD010611. doi: 10.1002/14651858.CD010611. Review.
Rao JS, Harry GJ, Rapoport SI, Kim HW Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010 Apr;15(4):384-92. doi: 10.1038/mp.2009.47. Epub 2009 Jun 2.
Rao JS, Keleshian VL, Klein S, Rapoport SI Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients. Transl Psychiatry. 2012 Jul 3;2:e132. doi: 10.1038/tp.2012.55.
Rao JS, Kim HW, Kellom M, Greenstein D, Chen M, Kraft AD, Harry GJ, Rapoport SI, Basselin M Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats. J Neuroinflammation. 2011 Aug 16;8:101. doi: 10.1186/1742-2094-8-101. Erratum in: J Neuroinflammation. 2012;9:19. Retraction in: J Neuroinflammation. 2017 May 9;14 (1):95.
Rao JS, Rapoport SI Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol. 2009 Jun;2(2):207-14. Review.
Rapoport SI, Basselin M, Kim HW, Rao JS Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev. 2009 Oct;61(2):185-209. doi: 10.1016/j.brainresrev.2009.06.003. Epub 2009 Jun 23. Review.
Rapoport SI Arachidonic acid and the brain. J Nutr. 2008 Dec;138(12):2515-20.
Reese EA, Cheon Y, Ramadan E, Kim HW, Chang L, Rao JS, Rapoport SI, Taha AY Gabapentin's minimal action on markers of rat brain arachidonic acid metabolism agrees with its inefficacy against bipolar disorder. Prostaglandins Leukot Essent Fatty Acids. 2012 Aug-Sep;87(2-3):71-7. doi: 10.1016/j.plefa.2012.06.003. Epub 2012 Jul 27.
Ruissen AM, Widdershoven GA, Meynen G, Abma TA, van Balkom AJ A systematic review of the literature about competence and poor insight. Acta Psychiatr Scand. 2012 Feb;125(2):103-13. doi: 10.1111/j.1600-0447.2011.01760.x. Epub 2011 Sep 8. Review.
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993 Jun;88(6):791-804.
Shimshoni JA, Basselin M, Li LO, Coleman RA, Rapoport SI, Modi HR Valproate uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: relevance to valproate's efficacy against bipolar disorder. Biochim Biophys Acta. 2011 Mar;1811(3):163-9. doi: 10.1016/j.bbalip.2010.12.006. Epub 2010 Dec 22.
Siddiqui O, Hung HM, O'Neill R MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009;19(2):227-46. doi: 10.1080/10543400802609797.
Snaith RP, Harrop FM, Newby DA, Teale C Grade scores of the Montgomery-Asberg Depression and the Clinical Anxiety Scales. Br J Psychiatry. 1986 May;148:599-601.
Vieta E Guide to Assessment Scales in Bipolar Disorder. 2 ed. London, UK: Current Medicine Group Ltd; 2010.
Vinokur AD, van Ryn M Social support and undermining in close relationships: their independent effects on the mental health of unemployed persons. J Pers Soc Psychol. 1993 Aug;65(2):350-9.
Who The World Health Report: 2001: Mental health: new understanding, new hope. Geneva: World Health Organization; 2001.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.